
Core Insights - INmune Bio Inc. has successfully completed its Phase I/II trial of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC), meeting both primary and secondary endpoints, and is now closed to further enrollment [1][2] - INKmune™ demonstrated an excellent safety profile across all three dose levels, with significant improvements in NK cell activation biomarkers observed in patients with low NK cell activation [2][3] - The company plans to advance the INKmune™ program by designing a randomized Phase 2b trial targeting patients with less severe disease to better measure the drug's effects and potential clinical benefits [3] Product Overview - INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line that primes resting NK cells to become tumor-killing memory-like NK cells, with effects persisting for over 100 days [4] - The treatment is patient-friendly, requiring no pre-medication or additional cytokine therapy, and can be administered via simple intravenous infusion as an outpatient procedure [5] - INKmune™ is tumor agnostic, applicable to various NK-resistant tumors, including leukemia, lymphoma, myeloma, and several solid tumors [5] Company Background - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat diseases [6] - The company has three product platforms: DN-TNF for chronic inflammation and cognitive disorders, Natural Killer Cell Priming Platform including INKmune™, and CORDStrom™ for regenerative medicine [6]